HK1210154A1 - 作為抗癌劑之高選擇性 抑制物 - Google Patents

作為抗癌劑之高選擇性 抑制物

Info

Publication number
HK1210154A1
HK1210154A1 HK15110897.6A HK15110897A HK1210154A1 HK 1210154 A1 HK1210154 A1 HK 1210154A1 HK 15110897 A HK15110897 A HK 15110897A HK 1210154 A1 HK1210154 A1 HK 1210154A1
Authority
HK
Hong Kong
Prior art keywords
met
anticancer agents
highly selective
inhibitors
met inhibitors
Prior art date
Application number
HK15110897.6A
Other languages
English (en)
Inventor
Boyu Zhong
Chuan Shih
Hongbin Yuan
Feng Zhou
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of HK1210154A1 publication Critical patent/HK1210154A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15110897.6A 2012-09-03 2015-11-04 作為抗癌劑之高選擇性 抑制物 HK1210154A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012103223591A CN103122000B (zh) 2012-09-03 2012-09-03 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
PCT/CN2013/080598 WO2014032498A1 (en) 2012-09-03 2013-08-01 Highly selective c-met inhibitors as anticancer agents

Publications (1)

Publication Number Publication Date
HK1210154A1 true HK1210154A1 (zh) 2016-04-15

Family

ID=48453178

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110897.6A HK1210154A1 (zh) 2012-09-03 2015-11-04 作為抗癌劑之高選擇性 抑制物

Country Status (6)

Country Link
US (1) US9695175B2 (zh)
EP (1) EP2892904B1 (zh)
JP (1) JP6106899B2 (zh)
CN (1) CN103122000B (zh)
HK (1) HK1210154A1 (zh)
WO (1) WO2014032498A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105326793A (zh) * 2014-08-06 2016-02-17 中美冠科生物技术（太仓）有限公司 一种包含c-Met激酶抑制剂的固体分散体及其制备方法和用途
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109206357A (zh) * 2017-07-04 2019-01-15 浙江九洲药业股份有限公司 一种格列齐特中间体的通式化合物及其制备方法和应用
CN112424222A (zh) * 2018-02-17 2021-02-26 冠科美博有限公司 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗
JP2022513215A (ja) * 2018-12-14 2022-02-07 ベータ・ファーマ・インコーポレイテッド Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020244654A1 (en) * 2019-06-06 2020-12-10 Apollomics Inc. (Hangzhou) Method for treating cancer patients using c-met inhibitor
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3181336A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113105436B (zh) * 2021-04-20 2022-07-01 西格莱(苏州)生物医药有限公司 吡唑类化合物的制备方法及其中间体
CN116283997A (zh) * 2022-09-08 2023-06-23 药康众拓(江苏)医药科技有限公司 氘代hgfr抑制剂药物及用途
WO2024068950A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024115512A1 (en) 2022-11-30 2024-06-06 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives
CN116854694B (zh) * 2023-07-04 2024-07-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620292B1 (pt) * 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
PL2081937T3 (pl) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
ES2393130T3 (es) * 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Triazoles bicíclicos como moduladores de proteínas quinasas
SI2081937T1 (sl) * 2006-10-23 2012-11-30 Sgx Pharmaceuticals Inc Triazolopiridazinski modulatorji proteinskih kinaz
CA2717034A1 (en) * 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer

Also Published As

Publication number Publication date
EP2892904A4 (en) 2016-04-06
JP2015526486A (ja) 2015-09-10
CN103122000A (zh) 2013-05-29
US9695175B2 (en) 2017-07-04
US20150218171A1 (en) 2015-08-06
JP6106899B2 (ja) 2017-04-05
EP2892904B1 (en) 2018-10-17
CN103122000B (zh) 2013-12-25
WO2014032498A1 (en) 2014-03-06
EP2892904A1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
HRP20181849T1 (hr) Triciklični spojevi kao antikancerogeni agensi
HK1210154A1 (zh) 作為抗癌劑之高選擇性 抑制物
HK1212984A1 (zh) 咪唑並吡啶化合物
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2823830A4 (en) MESH-HIGHNESS MEDIUM
EP2864289A4 (en) CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS USEFUL AS ANTI-TUMOR AGENTS
EP2804611A4 (en) COMPOSITIONS FROM CHITOSAN
HK1203811A1 (zh) 抗癌劑
HK1202859A1 (zh) 抗瘧劑
EP2842561A4 (en) MEANS FOR OPTIMIZING THE ENTERAL ENVIRONMENT
ZA201408094B (en) Anti-malarial agents
GB201201287D0 (en) Compositions
EP2837387A4 (en) ANTICANCER AGENT
EP2889035A4 (en) ANTI-TUMOR AGENT
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
HUE045654T2 (hu) Anyagkeverékek
ZA201400726B (en) Anticancer agent
RS55201B1 (sr) Antimalarijski agensi
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201208751D0 (en) Anti-malarial compounds
GB201203082D0 (en) Compositions
GB201203083D0 (en) Compositions